Lotte Biologics to seek CDMO partnerships at DCAT Week 2026

Lotte Biologics said it will participate in Drug, Chemical & Associated Technologies Association (DCAT) Week 2026, a global pharmaceutical and bio industry business event held in New York City from March 23 to 26.

The company will use the event to pursue global CDMO partnership opportunities while highlighting the capabilities of its Syracuse bio campus and the upcoming completion of Plant 1 at its Songdo bio campus.

Lotte Biologics will participate in DCAT Week 2026 in New York from Mar. 23 to 26 to pursue global CDMO partnership opportunities while highlighting its Syracuse bio campus capabilities and the upcoming completion of Plant 1 at its Songdo bio campus. The photo shows Lotte Biologics' plant in Syracuse, New York, the U.S. (credit: Lotte Biologics)

DCAT Week is a major international networking event in the pharmaceutical and bio industry held annually in New York, where global pharmaceutical companies and contract development and manufacturing organizations gather to explore partnership opportunities.

The company will operate a separate meeting room at the Lotte New York Palace, where the event is held, and seek opportunities for global contract development and manufacturing organization business cooperation, including in the North American market.

Notably, the company plans to engage in partnership discussions by highlighting the synergy between the accumulated quality capabilities of its Syracuse bio campus in New York and the large-scale production capacity of Plant 1 at the Songdo bio campus in Incheon, which is scheduled to be completed in August.

The company will also emphasize that it is strengthening its service delivery capabilities through strategic collaboration.

Specifically, through a partnership with Asimov signed in March 2025, the company said it can complete cell line development through drug substance production within about 8.5 months.

The company will also highlight its ability to provide step-by-step manufacturing options from clinical trial stages to good manufacturing practice (GMP) production, as well as development and manufacturing support for various modalities such as monoclonal antibodies and bispecific antibodies.

“DCAT Week is an important event where major decision-makers in the global pharmaceutical and bio industry gather in one place,” a Lotte Biologics official said. “Through our participation, we plan to seek cooperation opportunities with potential clients and continue expanding our competitiveness in the global market.”